Repligen (NASDAQ:RGEN) Releases FY 2024 Earnings Guidance

Repligen (NASDAQ:RGEN) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.420-1.490 for the period, compared to the consensus estimate of 1.460. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $635.6 million. Repligen also updated its FY24 guidance to $1.42-1.49 EPS.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. KeyCorp lifted their price target on shares of Repligen from $210.00 to $220.00 and gave the company an overweight rating in a research report on Thursday, February 15th. Stifel Nicolaus lifted their price objective on shares of Repligen from $165.00 to $207.00 and gave the stock a buy rating in a report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average target price of $196.70.

Repligen Stock Performance

Shares of NASDAQ:RGEN traded down $8.87 during midday trading on Wednesday, reaching $155.33. The company had a trading volume of 277,428 shares, compared to its average volume of 530,222. The company’s 50 day moving average price is $182.66 and its 200 day moving average price is $173.96. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26. The stock has a market cap of $8.67 billion, a P/E ratio of 228.06, a P/E/G ratio of 5.44 and a beta of 1.02. Repligen has a 52-week low of $110.45 and a 52-week high of $211.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.33. The company had revenue of $155.74 million for the quarter, compared to the consensus estimate of $155.38 million. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The firm’s quarterly revenue was down 16.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.68 EPS. As a group, sell-side analysts anticipate that Repligen will post 1.46 EPS for the current fiscal year.

Insider Activity at Repligen

In related news, Director Karen A. Dawes sold 1,000 shares of the business’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the sale, the director now directly owns 87,367 shares in the company, valued at approximately $16,892,409.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares in the company, valued at $4,699,889.80. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Karen A. Dawes sold 1,000 shares of the company’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total value of $193,350.00. Following the sale, the director now owns 87,367 shares in the company, valued at $16,892,409.45. The disclosure for this sale can be found here. In the last three months, insiders have sold 25,597 shares of company stock worth $5,039,532. Company insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.